Badania kliniczne

Ostra białaczka szpikowa

A MULTICENTER, OPEN, NON-COMPARATIVE, PHASE II STUDY OF THE COMBINATION OF CLADRIBINE (2-CHLORODEOXYADENOSINE), CYTARABINE, AND G-CSF AS INDUCTION THERAPY IN REFRACTORY ACUTE MYELOID LEUKEMIA – A REPORT OF THE POLISH ADULT LEUKEMIA GROUP (PALG) (2003)
A MULTICENTER, OPEN, NONCOMPARATIVE, PHASE II STUDY OF THE COMBINATION OF CLADRIBINE (2-CHLORODEOXYADENOSINE), CYTARABINE, GRANULOCYTE COLONY-STIMULATING FACTOR AND MITOXANTRONE AS INDUCTION THERAPY IN REFRACTORY ACUTE MYELOID LEUKEMIA: A REPORT OF THE POLISH ADULT LEUKEMIA GROUP (2005)
ADDITION OF CLADRIBINE TO INDUCTION/CONSOLIDATION REGIMEN DOES NOT IMPAIR PERIPHERAL BLOOD STEM CELL MOBILIZATION AND BONE MARROW HARVEST FOR AUTOTRANSPLANTATION IN ACUTE MYELOID LEUKEMIA PATIENTS (2005)
FLUDARABINE, CYTARABINE, AND MITOXANTRONE (FLAM) FOR THE TREATMENT OF RELAPSED AND REFRACTORY ADULT ACUTE LYMPHOBLASTIC LEUKEMIA. A PHASE STUDY BY THE POLISH ADULT LEUKEMIA GROUP (PALG) (2006)
CLADIBINE COMBINED WITH HIGH DOSES OF ARABINOSIDE CYTOSINE, MITOXANTRONE AND G-CSF (CLAG-M) IS A HIGHLY EFFECTIVE SALVAGE REGIMEN IN PATIENTS WITH REFRACTORY AND RELAPSED ACUTE MYELOID LEUKEMIA OF THE POOR RISK: A FINAL REPORT OF THE POLISH ADULT LEUKEMIA GROUP (2008)
DAUNORUBICIN, CYTARABINE AND FLUDARABINE (DAF) FOR REMISSION INDUCTION IN RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA. EVALUATION OF SAFETY, TOLERANCE AND EARLY OUTCOME – POLISH ADULT LEUKEMIA GROUP (PALG) PILOT STUDY (2008)
STATUS OF MINIMAL RESIDUAL DISEASE AFTER INDUCTION PREDICTS OUTCOME IN BOTH STANDARD AND HIGH-RISK PH-NEGATIVE ADULT ACUTE LYMPHOBLASTIC LEUKAEMIA. THE POLISH ADULT LEUKEMIA GROUP ALL 4-2002 MRD STUDY (2008)
INFECTIOUS COMPLICATIONS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED ACCORDING TO THE PROTOCOL WITH DAUNORUBICIN AND CYTARABINE WITH OR WITHOUT ADDITION OF CLADRIBINE. A MULTICENTER STUDY BY THE POLISH ADULT LEUKEMIA GROUP (PALG) (2010)
THE EARLY REDUCTION OF LEUKEMIC BLASTS IN BONE MARROW ON DAY 6 OF INDUCTION TREATMENT IS PREDICTIVE FOR COMPLETE REMISSION RATE AND SURVIVAL IN ADULT ACUTE MYELOID LEUKEMIA; THE RESULTS OF MULTICENTER, PROSPECTIVE POLISH ADULT LEUKEMIA GROUP STUDY (2011)
TREATMENT OF ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA ADJUSTED FOR PERFORMANCE STATUS AND PRESENCE OF COMORBIDITIES: A POLISH ADULT LEUKEMIA GROUP STUDY (2015)
ASSESSING THE EFFICACY OF ALLOGENEIC HEMATOPOIETIC STEM CELLS TRANSPLANTATION (ALLO-HSCT) BY ANALYZING SURVIVAL END POINTS IN DEFINED GROUPS OF ACUTE MYELOID LEUKEMIA PATIENTS: A RETROSPECTIVE, MULTICENTER POLISH ADULT LEUKEMIA GROUP STUDY (2015)
AZACITIDINE USE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION-RESULTS FROM THE POLISH ADULT LEUKEMIA GROUP (2016)
CONCOMITANCE OF MONOSOMAL KARYOTYPE WITH AT LEAST 5 CHROMOSOMAL ABNORMALITIES IS ASSOCIATED WITH DISMAL TREATMENT OUTCOME OF AML PATIENTS WITH COMPLEX KARYOTYPE – RETROSPECTIVE ANALYSIS OF POLISH ADULT LEUKEMIA GROUP (PALG) 2(017)
ADDITION OF CLADRIBINE TO THE STANDARD INDUCTION TREATMENT IMPROVES OUTCOMES IN A SUBSET OF ELDERLY ACUTE MYELOID LEUKEMIA PATIENTS. RESULTS OF A RANDOMIZED POLISH ADULT LEUKEMIA GROUP (PALG) PHASE II TRIAL (2017)
Early induction intensification with cladribine, cytarabine, and mitoxantrone (CLAM) in AML patients treated with the DAC induction regimen: a prospective, non-randomized, phase II study of the Polish Adult Leukemia Group (PALG). (2020)
Outcome of a Real-Life Population of Patients With Acute Promyelocytic Leukemia Treated According to the PETHEMA Guidelines: The Polish Adult Leukemia Group (PALG) Experience. (2021)

Przewlekła białaczka limfocytowa

COMPARISON OF CLADRIBINE PLUS PREDNISONE WITH CHLORAMBUCIL PLUS PREDNISONE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA. FINAL REPORT OF THE POLISH ADULT LEUKEMIA GROUP (PALG CLL1) (2005)
PALG CLL-1
CLADRIBINE ALONE AND IN COMBINATION WITH CYCLOPHOSPHAMIDE OR CYCLOPHOSPHAMIDE PLUS MITOXANTRONE IN THE TREATMENT OF PROGRESSIVE CHRONIC LYMPHOCYTIC LEUKEMIA: REPORT OF A PROSPECTIVE, MULTICENTER, RANDOMIZED TRIAL OF THE POLISH ADULT LEUKEMIA GROUP (PALG CLL2) (2006)
PALG CLL-2
ACTIVITY OF CLADRIBINE COMBINED WITH CYCLOPHOSPHAMIDE IN FRONTLINE THERAPY FOR CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P13.1/TP53 DELETION REPORT FROM THE POLISH ADULT LEUKEMIA GROUP (2009)
COMPARISON OF CLADRIBINE PLUS CYCLOPHOSPHAMIDE WITH FLUDARABINE PLUS CYCLOPHOSPHAMIDE AS FIRST-LINE THERAPY FOR CHRONIC LYMPHOCYTIC LEUKEMIA: A PHASE III RANDOMIZED STUDY BY THE POLISH ADULT LEUKEMIA GROUP (PALG-CLL3 STUDY) (2010)
PALG CLL-3
LONG-TERM RESULTS OF THE POLISH ADULT LEUKEMIA GROUP PALG-CLL2 PHASE III RANDOMIZED STUDY COMPARING CLADRIBINE-BASED COMBINATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA (2014)
PALG-CLL2
EFFICIACY AND TOXICITY OF COMPASSIONATE IBRUTINIB USE IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA IN POLAND: ANALYSIS OF THE POLISH ADULT LEUKEMIA GROUP (PALG) (2017)
ANALYSIS OF IBRUTINIB EFFICACY IN A SUBGROUP OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WITH 17P DELETION: OBSERVATIONAL STUDY OF THE POLISH ADULT LEUKEMIA GROUP (PALG) (2017)
HODGKIN’S VARIANT OF RICHTER’S TRANSFORMATION DURING IBRUTINIB THERAPY IN A SERIES OF CLL PATIENTS; THE POLISH ADULT LEUKEMIA GROUP (PALG) (2018)
EFFICACY AND SAFETY OF OBINUTUZUMAB-CHLORAMBUCIL COMBINATION IN THE FRONTLINE TREATMENT OF ELDERLY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND COMORBIDITIES REAL-LIFE DATA FROM POLISH ADULT LEUKEMIA GROUP (PALG) ANALYSIS (2018)
COMPARABLE EFFICACY OF IDELALISIB PLUS RITUXIMAB AND IBRUTINIB IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: A RETROSPECTIVE CASE MATCHED STUDY OF THE POLISH ADULT LEUKEMIA GROUP (PALG) (2018)
IBRUTINIB DISCONTINUATION IN PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA TREATED IN A COMPASSIONATE USE PROGRAM: A REPORT FROM THE POLISH ADULT LEUKEMIA STUDY GROUP (PALG) (2019)
Clinical efficacy and tolerability of venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia-a real-world analysis of the Polish Adult Leukemia Study Group. (2023)

Nowotwory mieloproliferacyjne i zespoły mielodysplastyczne

A MULTICENTER PROSPECTIVE STUDY ON EFFICACY AND SAFETY OF IMATINIB GENERICS: A REPORT FROM POLISH ADULT LEUKEMIA GROUP IMATINIB GENERICS REGISTRY (2017)
ARE MYELODYSPLASTIC SYNDROMES UNDERDIAGNOSED IN POLAND? A REPORT BY THE POLISH ADULT LEUKAEMIA GROUP (2017)
COMORBIDITY BURDEN AND USE OF CONCOMITANT MEDICATIONS AT CML DIAGNOSIS: A RETROSPECTIVE ANALYSIS OF 527 PATIENTS FROM THE POLISH ADULT LEUKEMIA GROUP REGISTRY (2018)
ATYPICAL CHRONIC MYELOID LEUKAEMIA: A CASE OF AN ORPHAN DISEASE-A MULTICENTER REPORT BY THE POLISH ADULT LEUKEMIA GROUP (2018)
PREDICTIVE MODEL FOR INFECTION RISK IN MYELODYSPLASTIC SYNDROMES, ACUTE MYELOID LEUKEMIA, AND CHRONIC MYELOMONOCYTIC LEUKEMIA PATIENTS TREATED WITH AZACITIDINE; AZACITIDINE INFECTION RISK MODEL: THE POLISH ADULT LEUKEMIA GROUP STUDY (2019)
Analysis of Predictive Factors for Early Response to Ruxolitinib in 320 Patients with Myelofibrosis From the Polish Adult Leukemia Group (PALG) Registry. (2023)